GHRH analoguesGHRH analogueAn analogue of growth-hormone-releasing hormone (GHRH) that prompts the pituitary to release its own GH.
Sermorelin vs CJC-1295 vs Tesamorelin
The table compares the compounds’ key data from their entry pages. Open each compound’s full entry for details. Educational content, not medical advice.
 Sermorelin |  CJC-1295 |  Tesamorelin | |
|---|---|---|---|
| What it is | GHRH(1-29) analog: physiological GH restoration | GHRH analog: sustained growth hormone stimulation | GHRH analog: visceral fat reduction (FDA-approved) |
| Type | GHRH(1-29) analog | GHRH analog (DAC) | GHRH analog (modified) |
| Structure | 29 aa GHRH fragment | 30 aa + DAC (maleimidopropionyl-D-Lys) | trans-3-hexenoyl-hGRF(1-44)NH₂ |
| Molecular weight | ~3358 Da | ~3647 Da (DAC) / ~3367 Da (no-DAC) | ~5135 Da |
| Target area | GH/IGF-1 | GH/IGF-1 | Visceral fat (HIV lipodystr.) |
| Storage | 2–8°C (reconstituted) | 2–8°C (reconstituted) | 2–8°C (reconstituted) |
| Stability | 14–21 days (reconstituted) | 25–30 days (reconstituted) | ~7 days (per label) |
| Full entry | Open → | Open → | Open → |
What it is
SermorelinGHRH(1-29) analog: physiological GH restoration
CJC-1295GHRH analog: sustained growth hormone stimulation
TesamorelinGHRH analog: visceral fat reduction (FDA-approved)
Type
SermorelinGHRH(1-29) analog
CJC-1295GHRH analog (DAC)
TesamorelinGHRH analog (modified)
Structure
Sermorelin29 aa GHRH fragment
CJC-129530 aa + DAC (maleimidopropionyl-D-Lys)
Tesamorelintrans-3-hexenoyl-hGRF(1-44)NH₂
Molecular weight
Sermorelin~3358 Da
CJC-1295~3647 Da (DAC) / ~3367 Da (no-DAC)
Tesamorelin~5135 Da
Target area
SermorelinGH/IGF-1
CJC-1295GH/IGF-1
TesamorelinVisceral fat (HIV lipodystr.)
Storage
Sermorelin2–8°C (reconstituted)
CJC-12952–8°C (reconstituted)
Tesamorelin2–8°C (reconstituted)
Stability
Sermorelin14–21 days (reconstituted)
CJC-129525–30 days (reconstituted)
Tesamorelin~7 days (per label)